In this guest contribution, Dilara Bahceci, PhD, explores the confluence of economic, regulatory and research-related barriers that have conspired to effectively disincentivise the development of generic ketamine for depressive disorders.Drawing on a recent article she co-authored with colleagues in Australia (Rodgers et al., 2023), Dr. Bahceci sheds light on the story of Spravato’s commercial…


Previous articleEuropean Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients
Next articlePα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs